Alpha 2.0
Login Register
» Authors » Malgorzata Czystowska

Malgorzata Czystowska

Explore the profile of Malgorzata Czystowska including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 980
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
Theresa L Whiteside
Marta Szajnik
Miroslaw J Szczepanski
Magis Mandapathil
Laura Strauss
Stephan Lang
William Gooding
Eva Wieckowski
Christoph Bergmann
Michael Boyiadzis
Published In
PLoS One
Cancer Immunol Immunother
Clin Cancer Res
Head Neck
Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC
Czystowska M, Gooding W, Szczepanski M, Lopez-Abaitero A, Ferris R, Johnson J, et al.
Clin Cancer Res . 2013 Feb; 19(4):889-99. PMID: 23363813
Purpose: Patients with cancer have an increased frequency of circulating apoptosis-sensitive CD8(+)CCR7(neg) T cells and few CD8(+)CCR7(+) T cells versus normal controls. The functional and clinical significance of this imbalance...
2.
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Rahma O, Ashtar E, Czystowska M, Szajnik M, Wieckowski E, Bernstein S, et al.
Cancer Immunol Immunother . 2011 Sep; 61(3):373-84. PMID: 21927947
Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In...
3.
Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic
Czystowska M, Szczepanski M, Szajnik M, Quadrini K, Brandwein H, Hadden J, et al.
Cancer Immunol Immunother . 2010 Dec; 60(4):495-506. PMID: 21181158
Objectives: IRX-2 is a novel immunotherapeutic containing physiologic quantities of several cytokines which protects human T lymphocytes from tumor-induced or drug-induced apoptosis. Here, we investigate the mechanisms responsible for IRX-2-mediated...
4.
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg)
Szajnik M, Czystowska M, Szczepanski M, Mandapathil M, Whiteside T
PLoS One . 2010 Jul; 5(7):e11469. PMID: 20661468
Background: Tumor-derived microvesicles (TMV) or exosomes are present in body fluids of patients with cancer and might be involved in tumor progression. The frequency and suppressor functions of peripheral blood...
5.
Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2)
Czystowska M, Strauss L, Bergmann C, Szajnik M, Rabinowich H, Whiteside T
J Mol Med (Berl) . 2010 Mar; 88(6):577-88. PMID: 20225066
Human CD4(+)CD25(high)FOXP3(+) T regulatory cells (Treg) can suppress responder T cell (RC) functions by various mechanisms. In co-cultures of Treg and autologous activated RC, both cell subsets up-regulate the expression...
6.
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells
Mandapathil M, Hilldorfer B, Szczepanski M, Czystowska M, Szajnik M, Ren J, et al.
J Biol Chem . 2009 Oct; 285(10):7176-86. PMID: 19858205
Naturally occurring regulatory T cells (nTreg) are crucial for maintaining tolerance to self and thus preventing autoimmune diseases and allograft rejections. In cancer, Treg down-regulate antitumor responses by several distinct...
7.
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin
Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside T
PLoS One . 2009 Jun; 4(6):e5994. PMID: 19543393
Background: The immunosuppressive drug rapamycin (RAPA) promotes the expansion of CD4(+) CD25(high)Foxp3(+) regulatory T cells via mechanisms that remain unknown. Here, we studied expansion, IL-2R-gamma chain signaling, survival pathways and...
8.
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia
Szczepanski M, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al.
Clin Cancer Res . 2009 May; 15(10):3325-32. PMID: 19417016
Purpose: Regulatory CD4(+)CD25(high)Foxp3(+) T cells (Treg) control peripheral immune tolerance. Patients with cancer, including those with hematologic malignancies, have elevated numbers of Treg in the peripheral circulation and in tumor...
9.
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack
Szczepanski M, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al.
Cancer Res . 2009 Mar; 69(7):3105-13. PMID: 19318560
Toll-like receptors (TLR) expressed on inflammatory cells play a key role in host defense against pathogens, benefiting the host. TLR are also expressed on tumor cells. To evaluate the role...
10.
Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression
Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, et al.
Head Neck . 2008 Dec; 31(3):371-80. PMID: 19073006
Background: Tumor-derived membranous vesicles (MV) isolated from sera of the patients with squamous cell carcinomas of the head and neck (HNSCC) induce apoptosis of activated CD8(+) T cells. We tested...